DE602004025156D1 - Mikrosphären von Estradiol und Cholesterol - Google Patents

Mikrosphären von Estradiol und Cholesterol

Info

Publication number
DE602004025156D1
DE602004025156D1 DE200460025156 DE602004025156T DE602004025156D1 DE 602004025156 D1 DE602004025156 D1 DE 602004025156D1 DE 200460025156 DE200460025156 DE 200460025156 DE 602004025156 T DE602004025156 T DE 602004025156T DE 602004025156 D1 DE602004025156 D1 DE 602004025156D1
Authority
DE
Germany
Prior art keywords
estradiol
cholesterol
microspheres
progesterone
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200460025156
Other languages
English (en)
Inventor
John Claude Savoir
Uribe Juan Angeles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skendi Finance Ltd Virgin Islands
Original Assignee
Skendi Finance Ltd Virgin Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004025156(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skendi Finance Ltd Virgin Islands filed Critical Skendi Finance Ltd Virgin Islands
Publication of DE602004025156D1 publication Critical patent/DE602004025156D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE200460025156 2003-06-13 2004-06-10 Mikrosphären von Estradiol und Cholesterol Active DE602004025156D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13

Publications (1)

Publication Number Publication Date
DE602004025156D1 true DE602004025156D1 (de) 2010-03-04

Family

ID=33551788

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200460025156 Active DE602004025156D1 (de) 2003-06-13 2004-06-10 Mikrosphären von Estradiol und Cholesterol

Country Status (24)

Country Link
US (2) US7589082B2 (de)
EP (3) EP1663161B1 (de)
JP (2) JP4956185B2 (de)
CN (2) CN100594907C (de)
AT (1) ATE454885T1 (de)
AU (1) AU2004246870B2 (de)
BR (1) BRPI0411335A (de)
CA (2) CA2528545C (de)
CY (1) CY1109967T1 (de)
DE (1) DE602004025156D1 (de)
DK (3) DK1820494T3 (de)
EA (3) EA012783B1 (de)
ES (3) ES2537563T3 (de)
HK (4) HK1097735A1 (de)
HU (1) HUE025147T2 (de)
IL (2) IL172466A (de)
MX (1) MX2008014654A (de)
NO (1) NO341540B1 (de)
OA (1) OA13307A (de)
PL (3) PL1844765T3 (de)
PT (3) PT1820494E (de)
SI (3) SI1820494T1 (de)
TW (1) TWI336623B (de)
WO (1) WO2004110408A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1820494T1 (sl) 2003-06-13 2010-08-31 Skendi Finance Ltd Mikrodelci, ki sestojijo iz estradiola in holesterola
CN102056611A (zh) * 2008-04-14 2011-05-11 Posi维森纳里解决方案有限责任公司 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2701744A4 (de) * 2011-03-23 2014-08-20 Pop Test Cortisol Llc Kombinationstherapie
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
US20170281646A1 (en) * 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3272732B1 (de) 2016-07-19 2019-09-18 Evonik Degussa GmbH Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden
US11135229B2 (en) * 2018-11-29 2021-10-05 Insigna Inc. Cat and dog sterilization by estrogenic compounds
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) * 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (de) 1997-07-04 1999-01-07 PowderJect Research Limited Vorrichtung zur Abgabe von Medikamententeilchen
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
AU2742102A (en) * 2000-12-14 2002-06-24 Ortho Mcneil Pharm Inc Steroid hormone products and methods for preparing them
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
SI1820494T1 (sl) 2003-06-13 2010-08-31 Skendi Finance Ltd Mikrodelci, ki sestojijo iz estradiola in holesterola

Also Published As

Publication number Publication date
TWI336623B (en) 2011-02-01
PT1844765E (pt) 2015-05-20
DK1844765T3 (en) 2015-04-27
DK1820494T3 (da) 2010-05-25
HK1147426A1 (en) 2011-08-12
EP1663161B1 (de) 2015-01-14
HK1097735A1 (en) 2007-07-06
EP1820494A3 (de) 2007-09-19
AU2004246870A1 (en) 2004-12-23
NO20060200L (no) 2006-01-13
WO2004110408A2 (en) 2004-12-23
EA200900451A1 (ru) 2009-12-30
HUE025147T2 (hu) 2016-03-29
JP2006527263A (ja) 2006-11-30
CA2528545C (en) 2014-08-12
OA13307A (en) 2007-04-13
NO341540B1 (no) 2017-12-04
EA026709B1 (ru) 2017-05-31
CN101816662B (zh) 2015-01-28
US7589082B2 (en) 2009-09-15
IL210851A (en) 2016-05-31
EP1663161A2 (de) 2006-06-07
BRPI0411335A (pt) 2006-07-25
PL1663161T3 (pl) 2015-08-31
IL172466A (en) 2011-11-30
CA2528545A1 (en) 2004-12-23
SI1663161T1 (sl) 2015-05-29
SI1820494T1 (sl) 2010-08-31
ATE454885T1 (de) 2010-01-15
SI1844765T1 (sl) 2015-05-29
HK1109586A1 (en) 2008-06-13
CY1109967T1 (el) 2014-09-10
ES2537551T3 (es) 2015-06-09
TW200514560A (en) 2005-05-01
AU2004246870B2 (en) 2009-07-23
EA012783B1 (ru) 2009-12-30
CA2849228C (en) 2016-09-20
PL1844765T3 (pl) 2015-06-30
PT1663161E (pt) 2015-05-13
US8163722B2 (en) 2012-04-24
HK1106717A1 (en) 2008-03-20
EP1844765A1 (de) 2007-10-17
EA018356B1 (ru) 2013-07-30
WO2004110408A3 (en) 2005-04-14
CN1835737A (zh) 2006-09-20
DK1663161T3 (en) 2015-04-27
EA200600029A1 (ru) 2006-08-25
US20090081303A1 (en) 2009-03-26
PL1820494T3 (pl) 2010-07-30
CN100594907C (zh) 2010-03-24
MX2008014654A (es) 2009-03-09
CN101816662A (zh) 2010-09-01
IL172466A0 (en) 2006-04-10
EA201201221A1 (ru) 2014-02-28
EP1820494A2 (de) 2007-08-22
EP1820494B1 (de) 2010-01-13
EP1844765B1 (de) 2015-01-21
PT1820494E (pt) 2010-04-14
JP2011157386A (ja) 2011-08-18
ES2340422T3 (es) 2010-06-02
CA2849228A1 (en) 2004-12-23
US20050025827A1 (en) 2005-02-03
IL210851A0 (en) 2011-04-28
JP4956185B2 (ja) 2012-06-20
ES2537563T3 (es) 2015-06-09

Similar Documents

Publication Publication Date Title
ATE454885T1 (de) Mikrosphären von estradiol und cholesterol
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
HUP0300335A2 (hu) 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
WO2003104253A3 (de) 9-alpha-substituierte estratriene als selektiv wirksame estrogene
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
CY1116203T1 (el) Σκευασμα οιστραδιολης-προγεστερονης βραδειας αποδεσμευσης
SE0002354D0 (sv) New formulation
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
ATE355823T1 (de) Pharmazeutische zusammensetzung für die nasale verabreichung von östradiol und norethisteron
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms

Legal Events

Date Code Title Description
8364 No opposition during term of opposition